• Emelie Andersson, Shorena Janelidze, Björn Lampinen, Markus Nilsson, Antoine Leuzy, Erik Stomrud, Kaj Blennow, Henrik Zetterberg, and Oskar Hansson.
• Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden. Electronic address: emelie.andersson@med.lu.se.
• Neurobiol. Aging. 2020 Nov 1; 95: 143-153.

AbstractCerebrospinal fluid (CSF) neurofilament light (NfL) concentration has reproducibly been shown to reflect neurodegeneration in brain disorders, including Alzheimer's disease (AD). NfL concentration in blood correlates with the corresponding CSF levels, but few studies have directly compared the reliability of these 2 markers in sporadic AD. Herein, we measured plasma and CSF concentrations of NfL in 478 cognitively unimpaired (CU) subjects, 227 patients with mild cognitive impairment, and 113 patients with AD dementia. We found that the concentration of NfL in CSF, but not in plasma, was increased in response to Aβ pathology in CU subjects. Both CSF and plasma NfL concentrations were increased in patients with mild cognitive impairment and AD dementia. Furthermore, only NfL in CSF was associated with reduced white matter microstructure in CU subjects. Finally, in a transgenic mouse model of AD, CSF NfL increased before serum NfL in response to the development of Aβ pathology. In conclusion, NfL in CSF may be a more reliable biomarker of neurodegeneration than NfL in blood in preclinical sporadic AD.Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

30 keywords...

hide…